 |
市場調查報告書
商品編碼
1349862
黏多醣症(MPS)治療市場:各治療法，各MPS類型，各終端用戶，各地區- 規模，佔有率，展望，機會分析，2023年～2030年Mucopolysaccharidosis (MPS) Treatment Market, By Treatment, By MPS Type, By End User, By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030 |
||||||
預計到 2023 年，全球黏多醣貯積症 (MPS) 治療市場將達到 22.7 億美元，預測期內（2023-2030 年）複合年增長率為 10.1%。
| 報告目標範圍 | 報告詳細內容 | ||
|---|---|---|---|
| 基準年 | 2022 | 2023年的市場規模 | 美國:22億7,000萬美元 |
| 過去資料 | 從2018年~ 2021年 | 預測期間 | 2023-2030 |
| 預測期間2023年～2030年 年複合成長率: | 10.10% | 2030年的價值預測 | 美國:44億5,000萬美元 |
Muco多醣症 (MPS) 的治療主要著重於控制症狀、改善生活品質和減緩疾病進展。MPS 是一組罕見的遺傳性疾病，其特徵是細胞和組織中糖胺聚醣 (GAG) 積聚，這是由於分解這些複雜糖的特定?缺乏所致。酵素替代療法 (ERT)：這是許多類型 MPS 的主要治療方法。在 ERT 中，透過靜脈注射有缺陷或缺乏的酵素來幫助分解 GAG 積聚。雖然 ERT 有益，但它可能無法有效治療神經系統疾病，因為酵素可能無法有效穿過血腦屏障。造血幹細胞移植（HSCT）：造血幹細胞移植也稱為骨髓移植，涉及將捐贈者的健康幹細胞移植到患者的骨髓中。供體細胞可以產生有缺陷的?，這可能會減少 GAG 的累積。在病程早期、重大不可逆損傷之前進行造血幹細胞移植是最有效的。
市場動態
市場參與者正在關注各種無機成長策略，例如黏多醣貯積症（MPS）治療的合作研究，預計這將推動全球黏多醣貯積症（MPS）治療市場的成長。例如，2021年9月，武田製藥宣布，它是一家全球生物製藥公司，從患者的角度推動研發，旨在實現 "更好的健康" 和 "更光明的未來" 。與JCR Pharmaceuticals, Inc.合作，將其商業化下一代重組製劑JR-141，一種抗人轉鐵蛋白受體抗體和艾杜醣醛酸-2-硫酸酯?(IDS) 的融合蛋白，用於治療亨特氏症候群。已達成合作夥伴關係和許可協議。根據該協議，武田在美國境外銷售JR-141，包括加拿大、歐洲和其他地區（不包括日本和某些亞太國家）。JCR 將收到與此類非美國許可相關的預付款，並將有資格獲得額外的開發和銷售里程碑以及基於潛在銷售的分級特許權使用費。
本調查的主要特徵
- 本報告提供以2022年為基準年的預測期間（2023-2030 年）之全球黏多醣症(MPS)治療市場的市場規模和復合年增長率（CAGR %）相關的詳細分析。
- 並闡明不同部門市場的潛在收入機會，說明該市場具有魅力的投資主張矩陣。
- 同時並提供市場推動因素和限制、機會、新產品發布或批准、市場趨勢、區域前景和主要參與者採用的競爭戰略等重要考察。
- 並基於企業亮點，各類型投資組合、主要焦點、財務業績和市場策略等參數，介紹全球黏多醣症(MPS)治療市場的主要參與者之企業簡介。
- 藉由該報告提供的洞察，將能幫助營銷人員和公司高管能夠就未來的產品發布、類型升級、市場擴張和營銷策略做出明智的決策。
- 全球黏多醣症(MPS)治療市場報告配合該行業的各種利益相關者，包括投資者、供應商、產品製造商、分銷商、新進入者和金融分析師。
- 利益相關者可以透過全球黏多醣症(MPS)治療市場用於分析的各種戰略矩陣來幫助他們更容易做下決策。
目錄
第1章 調查目的與前提條件
- 調查目的
- 前提條件
- 簡稱
第2章 市場概況
- 報告概要
- 市場定義和範圍
- 摘要整理
- Coherent Opportunity Map(COM)
第3章 市場動態，法規，趨勢分析
- 市場動態
- 促進因素
- 阻礙因素
- 市場機會
- 影響分析
- 最近的醫藥品上市
- 流行病學
- 合併，收購，聯盟
- 法規情勢
- 主要的發展
- PEST分析
第4章 黏多醣症(MPS)治療的全球市場:COVID-19影響分析
- 經濟影響
- COVID-19流行病學
- 供需的影響
第5章 黏多醣症(MPS)治療的全球市場:不同治療，2018-2030年
- 酵素補充療法
- 幹細胞療法
第6章 黏多醣症(MPS)治療的全球市場:各MPS類型，2018-2030年
- MPS-I
- MPS-II
- MPS-IV
- MPS-VI
- MPS-VII
- 其他(MPS-III及MPS-IX)
第7章 黏多醣症(MPS)治療的全球市場:各終端用戶，2018年～2030年
- 醫院
- 專門診所
- 其他
第8章 黏多醣症(MPS)治療的全球市場:各地區，2018-2030年
- 北美
- 美國
- 加拿大
- 歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太地區
- 南美
- 巴西
- 墨西哥
- 阿根廷
- 其他南美國家
- 中東
- GCC
- 以色列
- 其他中東
- 非洲
- 北非
- 中非
- 南非
第9章 競爭情形
- 企業簡介
- Takeda Pharmaceutical Company Limited
- 設備·組合
- BioMarin Pharmaceuticals, Inc.
- 設備·組合
- Ultragenyx Pharmaceutical Inc.
- 設備·組合
- Sarepta Therapeutics
- 設備·組合
- Abeona Therapeutics Inc.
- 設備·組合
- Eloxx Pharmaceuticals
- 設備組合
- Esteve
- 設備組合
- Immusoft Corporation
- 設備組合
- Inventiva
- 設備組合
- GC Pharma
- 設備組合
- JCR Pharmaceuticals Co Ltd.
- 設備組合
- RegenxBio Inc.
- 設備組合
- Sangamo Therapeutics, Inc.
- 設備組合
- Bioasis Technologies Inc.
- 設備組合
- Paradigm Biopharmaceuticals Ltd.
- 設備組合
第10章 章節
- 參考文獻
- 調查手法
The global mucopolysaccharidosis (MPS) treatment market is estimated to be valued at US$ 2.27 Bn in 2023 and is expected to exhibit a CAGR of 10.1% during the forecast period (2023-2030).
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2022 | Market Size in 2023: | US$ 2.27 Bn |
| Historical Data for: | 2018 to 2021 | Forecast Period: | 2023 - 2030 |
| Forecast Period 2023 to 2030 CAGR: | 10.10% | 2030 Value Projection: | US$ 4.45 Bn |
The treatment of Mucopolysaccharidosis (MPS) is primarily focused on managing symptoms, improving the quality of life, and slowing down the progression of the disease. MPS is a group of rare genetic disorders characterized by the accumulation of glycosaminoglycans (GAGs) in cells and tissues due to deficiencies in specific enzymes responsible for breaking down these complex sugars. Enzyme Replacement Therapy (ERT): This is the mainstay treatment for many types of MPS. In ERT, the missing or deficient enzyme is administered intravenously to help break down the accumulated GAGs. Although ERT can be beneficial, it may not effectively treat neurological symptoms because the enzyme may not efficiently cross the blood-brain barrier. Hematopoietic Stem Cell Transplantation (HSCT): Also known as bone marrow transplantation, HSCT involves transplanting healthy stem cells from a donor into the patient's bone marrow. The donor cells can produce the missing enzyme, leading to a potential reduction in GAG accumulation. HSCT is most effective when performed early in the disease course before significant irreversible damage has occurred.
Market Dynamics
Market players are focusing on various inorganic growth strategies such as collaborations for the treatment mucopolysaccharidosis (MPS), which is expected to boost the global mucopolysaccharidosis (MPS) treatment market growth. For instance, In September 2021, Takeda Pharmaceuticals, a patient-focused, R&D-driven, global biopharmaceutical company committed to bringing Better Health and a Brighter Future, entered into an exclusive collaboration and license agreement with JCR Pharmaceuticals is a global specialty pharmaceuticals company, to commercialize JR-141, an investigational next-generation recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase (IDS) enzyme for the treatment of Hunter syndrome. Under the terms of the agreement, Takeda commercialized JR-141 outside of the U.S., including Canada, Europe, and other regions (excluding Japan and certain other Asia Pacific countries). JCR received an upfront payment for such an ex-US license and is eligible to receive additional development and commercial milestones, as well as tiered royalties on potential sales.
Key features of the study:
- This report provides an in-depth analysis of the global mucopolysaccharidosis (MPS) treatment market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global mucopolysaccharidosis (MPS) treatment market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
- Global mucopolysaccharidosis (MPS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global mucopolysaccharidosis (MPS) treatment market.
Detailed Segmentation:
- Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment:
- Enzyme Replacement Therapy
- Stem Cell Therapy
- Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type:
- MPS-I
- MPS-II
- MPS-IV
- MPS-VI
- MPS-VII
- Others (MPS-III and MPS-IX)
- Global Mucopolysaccharidosis (MPS) Treatment Market, By End User:
- Hospitals
- Specialty Clinics
- Others
- Global Mucopolysaccharidosis (MPS) Treatment, By Region:
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Takeda Pharmaceutical Company Limited
- BioMarin Pharmaceuticals, Inc.
- Ultragenyx Pharmaceutical Inc.
- Sarepta Therapeutics
- Abeona Therapeutics Inc.
- Eloxx Pharmaceuticals
- Esteve
- Immusoft Corporation
- Inventiva
- GC Pharma
- JCR Pharmaceuticals Co Ltd.
- RegenxBio Inc.
- Sangamo Therapeutics, Inc.
- Bioasis Technologies Inc.
- Paradigm Biopharmaceuticals Ltd.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Treatment
- Market Snippet, By MPS Type
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Drug Launches
- Epidemiology
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
4. Global Mucopolysaccharidosis (MPS) Treatment Market- COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
5. Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment, 2018-2030 (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Enzyme Replacement Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
- Stem Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Segment Trends
6. Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type, 2018-2030 (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- MPS-I
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- MPS-II
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- MPS-IV
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- MPS-VI
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- MPS-VII
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Others (MPS-III and MPS-IX)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
7. Global Mucopolysaccharidosis (MPS) Treatment Market, By End User, 2018-2030 (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
8. Global Mucopolysaccharidosis (MPS) Treatment Market, By Region, 2018-2030 (US$ Bn)
- Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018-2030
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country, and Y-o-Y Growth 2018-2030, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Treatment, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By MPS Type, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By End User, and Y-o-Y Growth 2018-2030, (US$ Bn)
- Market Size and Forecast, By Country/Region, and Y-o-Y Growth 2018-2030, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Company Profiles
- Takeda Pharmaceutical Company Limited
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- BioMarin Pharmaceuticals, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Ultragenyx Pharmaceutical Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sarepta Therapeutics
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Abeona Therapeutics Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Eloxx Pharmaceuticals
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Esteve
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Immusoft Corporation
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Inventiva
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GC Pharma
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- JCR Pharmaceuticals Co Ltd.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- RegenxBio Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Sangamo Therapeutics, Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Bioasis Technologies Inc.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- Paradigm Biopharmaceuticals Ltd.
- Company Overview
- Device Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
10. Section
- References
- Research Methodology
- About us and Sales Contact
